Effects of Glycometabolic Control on Macrovasculopathy in Diabetes: Evaluation and Suggestion_Chinese Journal of Evidence-Based Medicine

Authors：

周智广 , 陈小燕

Corresponding author：

Keywords：

Evidence- base d medicine; Diabetes mellitus; Macro angiopathy; Glucometabolic control

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 周智广,陈小燕. Effects of Glycometabolic Control on Macrovasculopathy in Diabetes: Evaluation and Suggestion. Chinese Journal of Evidence-Based Medicine, 2004, 04(7): 439-441. doi: Copy

1.	［1］Bartnik M,Malmberg K,Ryden L.Recognising and treating the diabetic patient in cardiovascular care[J].Eur J Cardiovasc Nurs,2002; 1(13):171-181.
2.	［2］Genuth S.A case for blood glucose control[J].Adv Int Med,1995; 40(34):573-623.
3.	［3］Diabetes Control and Complications Trail Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J].N Engl J Med,1993; 329(14):977-986.
4.	［4］UK Prospective Diabetes Study Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].Lancet,1998; 352(9 131):837-853.
5.	［5］UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) [J].BMJ,1998; 317(7 160):703-713.
6.	［6］Gaede P,Vedel P,Parving HH,Pedersen O.Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomized study[J].Lancet,1999; 353(9 153):617-622.
7.	［7］Chiasson JL,Gomis R,Hanefeld M,Josse RG,Karasik A,Laakso M.The STOP-NIDDM Trial:an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance:rationale,design and preliminary screening data.Study to Prevent Non-Insulin-Dependent Diabetes Mellitus[J].Diabetes Care,1998; 21(10):1 720-1 725.
8.	［8］Chiasson JL,Josse RG,Gomis R,Hanefeld M,Karasik A,Laakso M.Acarbose for prevention of type 2 diabetes mellitus:the stop-NIDDM randomised[J].Lancet,2002; 359(9 323):2 072-2 077.
9.	［9］The Diabetes Control and Complications Trail/ Epidemiology of Diabetes Interventions and Complications Research Group.Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus[J].N Engl Med,2003,348(23):2 294-2 303.
10.	［10］Malmberg K,Norhammar A,Wedel H,Rydén L.Glucometabolic state at admission important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction:long term results from the DIGAMI study[J].Circulation,1999; 99(20):2 626-2 632.
11.	［11］Norhammar A,Tener Z,Nilsson G,Hamsten A,Efendic S,Ryden L,Malmberg K.Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus:a prospective study[J].Lancet,2002; 359 (9 324):2 140-2 144.
12.	［12］Bastyr EJ 3rd,Stuart CA,Brodows RG,Schwartz S,Graf CJ,Zagar A,Robertson KE.Therapy focused on lowering postprandial glucose,not fasting glucose,may be superior for lowering HbA1c:IOEZ Study Group[J].Diabetes Care,2000; 23(9):1 236-1 241.
13.	［13］Colagiuri S,Cull CA,Holman RR.Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated With Improved Outcomes(UKPDS 61) [J]? Diabetes Care,2002; 25(7):1 410-1 417.
14.	［14］Arcavi L,Behar S,Caspi A,Reshef N,Boyko V,Knobler H.High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease:results from the Bezafibrate Infarction Prevention (BIP) study[J].Am Heart J,2004;147(20):239-245.
15.	［15］Meigs JB,Nathan DM,D’Agostino RB,Wilson PWF.Fasting and postchallenge glycemia and cardiovasculr disease risk:The Framingham Offspring Study[J].Diabetes Care,2002; 25(7):1 845-1 850.
16.	［16］Abrahamson MJ.Optimal glycemic control in type 2 diabetes mellitus:fasting and postprandial glucose in context[J].Arch Intern Med,2004;164(12):486-491.
17.	［17］Clark CM,Perry RC.Type 2 diabetes and macrovascular disease.Epidemiology and etiology[J].Am Heart J,1999;138(32):330-333.
18.	［18］Festa A,D’Agostino R Jr,Howard G,Mykkanen L,Tracy RP,Haffner SM.Chronic subclinical inflammation as part of the insulin resistance syndrome.The insulin resistance atherosclerosis study (IRAS)[J].Circulation,2000;102(21):42-47.
19.	［19］G(e)de P,Vedel P,Larsen N,Jensen GVH,Parving HH,Pederson O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes[J].N Engl J Med,2003; 348(5):383-393.
20.	［20］Wannamethee SG,Shaper AG,Perry IJ.Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men[J].Diabetes Care,2001; 24(4):1 590-1 595.
21.	［21］Dandona P,Aljada A,Chaudhuri A,Bandyopadhyay A.The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes[J].J Clin Endocrinol Metab,2003;88(6):2 422-2 429.

1. ［1］Bartnik M,Malmberg K,Ryden L.Recognising and treating the diabetic patient in cardiovascular care[J].Eur J Cardiovasc Nurs,2002; 1(13):171-181.
2. ［2］Genuth S.A case for blood glucose control[J].Adv Int Med,1995; 40(34):573-623.
3. ［3］Diabetes Control and Complications Trail Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J].N Engl J Med,1993; 329(14):977-986.
4. ［4］UK Prospective Diabetes Study Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].Lancet,1998; 352(9 131):837-853.
5. ［5］UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) [J].BMJ,1998; 317(7 160):703-713.
6. ［6］Gaede P,Vedel P,Parving HH,Pedersen O.Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomized study[J].Lancet,1999; 353(9 153):617-622.
7. ［7］Chiasson JL,Gomis R,Hanefeld M,Josse RG,Karasik A,Laakso M.The STOP-NIDDM Trial:an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance:rationale,design and preliminary screening data.Study to Prevent Non-Insulin-Dependent Diabetes Mellitus[J].Diabetes Care,1998; 21(10):1 720-1 725.
8. ［8］Chiasson JL,Josse RG,Gomis R,Hanefeld M,Karasik A,Laakso M.Acarbose for prevention of type 2 diabetes mellitus:the stop-NIDDM randomised[J].Lancet,2002; 359(9 323):2 072-2 077.
9. ［9］The Diabetes Control and Complications Trail/ Epidemiology of Diabetes Interventions and Complications Research Group.Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus[J].N Engl Med,2003,348(23):2 294-2 303.
10. ［10］Malmberg K,Norhammar A,Wedel H,Rydén L.Glucometabolic state at admission important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction:long term results from the DIGAMI study[J].Circulation,1999; 99(20):2 626-2 632.
11. ［11］Norhammar A,Tener Z,Nilsson G,Hamsten A,Efendic S,Ryden L,Malmberg K.Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus:a prospective study[J].Lancet,2002; 359 (9 324):2 140-2 144.
12. ［12］Bastyr EJ 3rd,Stuart CA,Brodows RG,Schwartz S,Graf CJ,Zagar A,Robertson KE.Therapy focused on lowering postprandial glucose,not fasting glucose,may be superior for lowering HbA1c:IOEZ Study Group[J].Diabetes Care,2000; 23(9):1 236-1 241.
13. ［13］Colagiuri S,Cull CA,Holman RR.Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated With Improved Outcomes(UKPDS 61) [J]? Diabetes Care,2002; 25(7):1 410-1 417.
14. ［14］Arcavi L,Behar S,Caspi A,Reshef N,Boyko V,Knobler H.High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease:results from the Bezafibrate Infarction Prevention (BIP) study[J].Am Heart J,2004;147(20):239-245.
15. ［15］Meigs JB,Nathan DM,D’Agostino RB,Wilson PWF.Fasting and postchallenge glycemia and cardiovasculr disease risk:The Framingham Offspring Study[J].Diabetes Care,2002; 25(7):1 845-1 850.
16. ［16］Abrahamson MJ.Optimal glycemic control in type 2 diabetes mellitus:fasting and postprandial glucose in context[J].Arch Intern Med,2004;164(12):486-491.
17. ［17］Clark CM,Perry RC.Type 2 diabetes and macrovascular disease.Epidemiology and etiology[J].Am Heart J,1999;138(32):330-333.
18. ［18］Festa A,D’Agostino R Jr,Howard G,Mykkanen L,Tracy RP,Haffner SM.Chronic subclinical inflammation as part of the insulin resistance syndrome.The insulin resistance atherosclerosis study (IRAS)[J].Circulation,2000;102(21):42-47.
19. ［19］G(e)de P,Vedel P,Larsen N,Jensen GVH,Parving HH,Pederson O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes[J].N Engl J Med,2003; 348(5):383-393.
20. ［20］Wannamethee SG,Shaper AG,Perry IJ.Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men[J].Diabetes Care,2001; 24(4):1 590-1 595.
21. ［21］Dandona P,Aljada A,Chaudhuri A,Bandyopadhyay A.The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes[J].J Clin Endocrinol Metab,2003;88(6):2 422-2 429.

Chinese Journal of Evidence-Based Medicine

Effects of Glycometabolic Control on Macrovasculopathy in Diabetes: Evaluation and Suggestion

Abstract Full text Figures/Tables Video References Cited by

Format

Content